PAK4抑制剂4-(3-1H-吲唑基)氨基喹唑啉衍生物的设计、合成及抗癌活性评价。

IF 3.3 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Bioorganic & Medicinal Chemistry Pub Date : 2023-10-13 DOI:10.1016/j.bmc.2023.117501
Wei Han , Yusang Yang , Fan Yu , Qianqian Li , Anyao Liu , Wenbo Xu , Jiabin Li , Xiaowen Xue
{"title":"PAK4抑制剂4-(3-1H-吲唑基)氨基喹唑啉衍生物的设计、合成及抗癌活性评价。","authors":"Wei Han ,&nbsp;Yusang Yang ,&nbsp;Fan Yu ,&nbsp;Qianqian Li ,&nbsp;Anyao Liu ,&nbsp;Wenbo Xu ,&nbsp;Jiabin Li ,&nbsp;Xiaowen Xue","doi":"10.1016/j.bmc.2023.117501","DOIUrl":null,"url":null,"abstract":"<div><p>A novel series of 4-(3-1<em>H</em>-indazolyl)amino quinazoline derivatives were developed as PAK4 inhibitors based on a scaffold hopping strategy. Compounds <strong>27e</strong>, <strong>27g</strong>, <strong>27i</strong> and <strong>27j</strong> were found to exhibit potent inhibitory activity against PAK4 (IC<sub>50</sub> = 10, 13, 11 and 9 nM, respectively). Subsequent cellular assay demonstrated that compound <strong>27e</strong> possessed the strongest antiproliferative activity against A549 cells with an IC<sub>50</sub> value of 0.61 μM, a little bit better than PF-3758309. Further anticancer mechanistic investigation revealed that compound <strong>27e</strong> significantly induced apoptosis of A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1. A docking model between compound <strong>27e</strong> and PAK4 was proposed to elucidate its possible binding modes. As a promising PAK4 inhibitor, compound <strong>27e</strong> may serve as a candidate for the development of novel PAK4-targeted anticancer drug.</p></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"95 ","pages":"Article 117501"},"PeriodicalIF":3.3000,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis and anticancer activity evaluation of 4-(3-1H-indazolyl)amino quinazoline derivatives as PAK4 inhibitors\",\"authors\":\"Wei Han ,&nbsp;Yusang Yang ,&nbsp;Fan Yu ,&nbsp;Qianqian Li ,&nbsp;Anyao Liu ,&nbsp;Wenbo Xu ,&nbsp;Jiabin Li ,&nbsp;Xiaowen Xue\",\"doi\":\"10.1016/j.bmc.2023.117501\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A novel series of 4-(3-1<em>H</em>-indazolyl)amino quinazoline derivatives were developed as PAK4 inhibitors based on a scaffold hopping strategy. Compounds <strong>27e</strong>, <strong>27g</strong>, <strong>27i</strong> and <strong>27j</strong> were found to exhibit potent inhibitory activity against PAK4 (IC<sub>50</sub> = 10, 13, 11 and 9 nM, respectively). Subsequent cellular assay demonstrated that compound <strong>27e</strong> possessed the strongest antiproliferative activity against A549 cells with an IC<sub>50</sub> value of 0.61 μM, a little bit better than PF-3758309. Further anticancer mechanistic investigation revealed that compound <strong>27e</strong> significantly induced apoptosis of A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1. A docking model between compound <strong>27e</strong> and PAK4 was proposed to elucidate its possible binding modes. As a promising PAK4 inhibitor, compound <strong>27e</strong> may serve as a candidate for the development of novel PAK4-targeted anticancer drug.</p></div>\",\"PeriodicalId\":255,\"journal\":{\"name\":\"Bioorganic & Medicinal Chemistry\",\"volume\":\"95 \",\"pages\":\"Article 117501\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic & Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0968089623003498\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0968089623003498","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

基于支架跳跃策略,开发了一系列新的4-(3-1H-吲唑基)氨基喹唑啉衍生物作为PAK4抑制剂。发现化合物27e、27g、27i和27j对PAK4表现出有效的抑制活性(IC50分别为10、13、11和9nM)。随后的细胞测定表明,化合物27e对A549细胞具有最强的抗增殖活性,IC50值为0.61μM,略好于PF-3758309。进一步的抗癌机制研究表明,化合物27e以浓度依赖性方式显著诱导A549细胞凋亡,并阻断G0/G1期的细胞周期。提出了化合物27e与PAK4之间的对接模型,以阐明其可能的结合模式。作为一种有前景的PAK4抑制剂,化合物27e可以作为开发新型PAK4靶向抗癌药物的候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Design, synthesis and anticancer activity evaluation of 4-(3-1H-indazolyl)amino quinazoline derivatives as PAK4 inhibitors

A novel series of 4-(3-1H-indazolyl)amino quinazoline derivatives were developed as PAK4 inhibitors based on a scaffold hopping strategy. Compounds 27e, 27g, 27i and 27j were found to exhibit potent inhibitory activity against PAK4 (IC50 = 10, 13, 11 and 9 nM, respectively). Subsequent cellular assay demonstrated that compound 27e possessed the strongest antiproliferative activity against A549 cells with an IC50 value of 0.61 μM, a little bit better than PF-3758309. Further anticancer mechanistic investigation revealed that compound 27e significantly induced apoptosis of A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1. A docking model between compound 27e and PAK4 was proposed to elucidate its possible binding modes. As a promising PAK4 inhibitor, compound 27e may serve as a candidate for the development of novel PAK4-targeted anticancer drug.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bioorganic & Medicinal Chemistry
Bioorganic & Medicinal Chemistry 医学-生化与分子生物学
CiteScore
6.80
自引率
2.90%
发文量
413
审稿时长
17 days
期刊介绍: Bioorganic & Medicinal Chemistry provides an international forum for the publication of full original research papers and critical reviews on molecular interactions in key biological targets such as receptors, channels, enzymes, nucleotides, lipids and saccharides. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. A special feature will be that colour illustrations will be reproduced at no charge to the author, provided that the Editor agrees that colour is essential to the information content of the illustration in question.
期刊最新文献
Esterase-responsive nanoparticles (ERN): A targeted approach for drug/gene delivery exploits Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications. Graphical abstract TOC Graphical abstract TOC Contents continued
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1